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Background: The Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a key factor for spindle assembly; its
deregulation is associated with numerous cancers.
Results: Phosphorylation of TPX2 at Thr72 regulates its spindle assembly functions via Aurora A and Eg5.
Conclusion: Proper regulation of TPX2 phosphorylation at Thr72 is required for spindle assembly.
Significance:Our study provides new mechanistic insights into the spindle and cancers-associated roles of TPX2.
The human ortholog of the targeting protein for Xenopus
kinesin-like protein 2 (TPX2) is a cytoskeletal protein that plays
a major role in spindle assembly and is required for mitosis.
During spindlemorphogenesis, TPX2cooperateswithAuroraA
kinase and Eg5 kinesin to regulate microtubule organization.
TPX2 displays over 40 putative phosphorylation sites identified
from various high-throughput proteomic screenings. In this
study, we characterize the phosphorylation of threonine 72
(Thr72) in human TPX2, a residue highly conserved across spe-
cies. We find that Cdk1/2 phosphorylate TPX2 in vitro and in
vivo. Using homemade antibodies specific for TPX2 phosphory-
lated at Thr72, we show that this phosphorylation is cell cycle-de-
pendent andpeaks atMphase. EndogenousTPX2phosphorylated
at Thr72 does not associate with themitotic spindle. Furthermore,
ectopic GFP-TPX2 T72A preferentially concentrates on the spin-
dle, whereas GFP-TPX2WT distributes to both spindle and cyto-
sol. The T72A mutant also increases the proportion of cells with
multipolar spindles phenotype. This effect is associated with
increased Aurora A activity and abnormally elongated spindles,
indicative of higher Eg5 activity. In summary, we propose that
phosphorylation ofThr72 regulatesTPX2 localization and impacts
spindle assembly via Aurora A and Eg5.
The Targeting protein for Xenopus kinesin-like protein 2
(TPX2)3 is a microtubule (MT)-associated protein critical for
spindle morphogenesis (1). This function of TPX2 is consistent
with its cell cycle-dependent expression that is lowest during
G1 phase and highest duringMphase (2). Duringmitosis, TPX2
associates withMTs and poles of the spindle, where it mediates
diverse functions. As indicated by its name, TPX2 localizes
Xklp2 to the spindle poles, a key event for spindle bipolarity (1).
TPX2 is also required forMTnucleation in the vicinity of chro-
mosomes and MT bundling (3–5). Depletion of TPX2 in HeLa
cells significantly decreases chromatin-mediated MTs nucle-
ation without affecting centrosome-mediated MT nucleation,
and causes mitotic block (5) as well as multipolar spindles (6).
Furthermore, primary cell cultures from a TPX2 knock-out
mouse display defects in MTs nucleation around the chromo-
somes, thereby leading to aberrant spindle formation and chro-
mosomemissegregation (7). Similarly, overexpression of TPX2
blocks spindle formation, arrests cells in prometaphase, and
causes spindle defects (5, 8).
TPX2 also contributes to MT branching during spindle
assembly. In this context, TPX2 cooperates with Augmin to
amplify MT mass and preserve MT polarity (9). In addition,
TPX2 activates Aurora A, a mitotic kinase important for sepa-
ration and maturation of centrosomes and for ensuring proper
formation of bipolar spindles (for a complete review of the
mechanism of action of TPX2 onAurora A (see Ref. 10)). Inter-
estingly, like TPX2 depletion or overexpression, both inactiva-
tion or amplification of Aurora A induces multipolar spindles
phenotypes (11–13). Finally, the localization and activity of
Eg5, a plus-end directed motor protein that belongs to the
Kinesin-5 subclass, is regulated by TPX2 (14). Eg5 affects
mitotic spindle organization and spindle assembly by MT
cross-linking, sliding alongMTs and generating outward forces
for spindle pole separation at mitotic entry (14, 15). In mam-
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malian cells, inhibition of the TPX2/Eg5 association causes
alterations inmitotic spindle length/polarity and enhancedMT
nucleation around chromosomes (14, 15). In summary, TPX2
promotes spindle assembly andmitosis in human cells through
multiple mechanisms.
AlthoughTPX2 contains 747 amino acids that predict amass
of 86 kDa, the observedmolecular mass on SDS-PAGE is about
100 kDa. This observation suggests post-translational modifi-
cations of the protein (16). PhosphoSitePlus, an online database
providing information on protein post-translational modifica-
tions shows that TPX2 has over 40 in vivo putative phosphory-
lation sites (17). In Xenopus egg extracts, TPX2 is phosphory-
lated specifically during mitosis and this can be enhanced by
taxol-mediated stabilization of mitotic MTs (18). Several puta-
tive cdc2 and MAP kinase sites were detected on TPX2 from
these extracts using mass spectrometry. Human TPX2 is also
phosphorylated duringMphase (2). Together, these data indicate
that the functionsofTPX2mightbe regulatedbyphosphorylation.
In particular, numerous high-throughput phosphoproteomic
screens and this study identified threonine 72 (Thr72), a highly
conserved residue among TPX2 species, as a potential phos-
phorylation site in human cells (19–32). However, this site has
never been validated and investigated. Based on the frequent
detection of Thr(P)72 peptides in phosphoproteome screens
(19–32) and our ownmass spectrometry of phospho-TPX2 sites,
we verified and characterized the phosphorylation of Thr72 in
cycling cells.Wepropose that phosphorylation at this residue reg-
ulates TPX2 localization and impacts spindle morphogenesis via
Aurora A and Eg5.
EXPERIMENTAL PROCEDURES
Mass Spectrometry Analysis—HeLa cells were synchronized
using 100 ng/ml of nocodazole for 16 h. After three PBS wash-
ings, cells were released into fresh DMEMwithout nocodazole
for 30 min. Cells were harvested and washed with PBS twice
before addition of lysis buffer. Protein lysate concentrations
were measured using the Bradford protein assay (Bio-Rad).
Endogenous TPX2 was immunoprecipitated from 10 mg of
total protein lysates using TPX2 Abs (clone 184, Novus Biolog-
icals) and Protein A/G-Sepharose 4 Fast Flow beads. The beads
were then washed five times with 500ml of lysis buffer contain-
ing protease inhibitors. The IP samples were run on SDS-
PAGE, andCoomassie Blue-stained bands around the expected
size of 100 kDa were excised from the gel and sent for mass
spectrometry analysis at the University of Victoria Proteomic
Center. Another set of IP samples was analyzed by Western
blotting using Thr(P)72 and pan-TPX2 Abs. Sample prepara-
tion for LC-MS/MS analysis was performed at the University of
Victoria Proteomic Center. For mass spectrometry data analy-
sis, raw files analyzed with Proteome Discoverer software
(Thermo Scientific) were submitted to Mascot 2.2 and com-
pared with Homo sapiens of Uniprot-Swissprot, Uniprot
Trembl, and IPI human database entries.
Generation of Phosphospecific Thr72 TPX2 Antibodies—The
phosphospecific Abs recognizing phospho-TPX2 at threonine
72 were raised in rabbit against the phosphopeptide
(K)LQQAIV(pT*72)PLKPVD that comprises amino acids 66 to
78 of human TPX2. The N-terminal lysine was added to pro-
mote solubility. The peptide was conjugated to keyhole limpet
hemocyanin (carrier for the phosphopeptide hapten) and was
used for immunization of rabbits. The phosphospecific Abs
were affinity purified from the antiserum using standard labo-
ratory protocols. Briefly, non-phosphorylated peptide or phos-
phorylated peptide was coupled to two different agarose
columns of SulfoLink coupling gel using SulfoLink Immobi-
lization kits (Pierce). Crude serum was first applied to the col-
umn coupled with non-phosphorylated peptide, then the flow-
through was applied to the column coupled with the
phosphorylated peptide. The phosphospecific Abs were eluted
from the phosphorylated peptide column.
In Vitro Cdk Kinase Assay—In vitro kinase assays were per-
formed using activeCdk-cyclin complexes andGST fusion pro-
teins. 10g ofGST-TPX2WT,T72A, andT72E fusion proteins
were incubatedwith 1g of each active Cdk1-cyclin B or Cdk2-
cyclin A in the presence of 1 mM ATP (Sigma) at 30 °C for 30
min in kinase buffer (25 mM Tris-HCl (pH 7.5), 5 mM -glycer-
ophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10
mM MgCl2, 8 mM MOPS (pH 7.0), 0.2 mM EDTA). As control,
10 g of GST-TPX2 protein was incubated with 1 mM ATP in
the same condition as above without any active Cdk-cyclin
complex. Kinase reactions were stopped by adding 5 SDS-
PAGE loading buffer into each sample. Western blot analysis
was performed with reaction products using TPX2 (clone 184,
Novus Biologicals), Thr(P)72, Cdk1, and Cdk2 Abs.
RNA Interference Sequences—Two unique TPX2-specific
siRNA oligos were used to knock down endogenous TPX2. The
first TPX2 siRNA oligo (5-GAAUGGAACUGGAGGGCUU-
3; called TPX2 cds siRNA in this paper) has been described
previously and specificity has been thoroughly demonstrated
(5). This TPX2 cds siRNA targets a coding region of human
TPX2 (hTPX2) 160–179 bp from the start codon. The second
siRNA oligo (5-AAGGCTAATAATGAGATCTAA-3; called
TPX2 UTR siRNA in this paper) targets a 3 untranslated
region (3UTR) of hTPX2mRNA. This TPX2 UTR siRNAwas
purchased fromQiagen and was validated previously (33). “All-
Stars negative control siRNA” (Qiagen) was used as a negative
control.
Generation of GFP-TPX2 Wild-type and Mutant Constructs—
To generate the GFP-TPX2 wild-type vector, human TPX2
cDNA (bp 3–2241) was cloned into pEGFP-C1 (Clontech).
Site-directed mutagenesis was carried out on this plasmid to
generate the T72Amutant. GFP-TPX2 T72A was generated by
PCR using a mutation primer set (5 phosphorylated T72A for-
ward primer: CAAGCTATTGTCGCACCTTTGAAACCAG
and 5phosphorylated T72A reverse primer: CTGAAGATT-
AGCCTTTCTCAAAGGAG) and Phusion Hot Start DNA
Polymerase (Finnzymes) to mutate threonine (ACA) to alanine
(GCA). Mutated PCR products were circularized by ligation
using a Rapid DNA ligation kit (Thermo Scientific). The muta-
tion was confirmed by DNA sequencing.
Protein Extraction and Western Blotting—After PBS wash-
ing, cells were lysed in an appropriate volume of mild and non-
denaturing lysis buffer (20mMTris-HCl (pH7.5), 150mMNaCl,
1 mM Na2EDTA, 1 mM EGTA, 1% (v/v) Triton, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1
mMphenylmethylsulfonyl fluoride (PMSF), a protease inhibitor
TPX2 Phosphorylation at Thr72
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mixture tablet (Roche Applied Science), and 1 mM microcys-
tin-LR (Cayman chemical)). Lysates were incubated on ice for
10 min and sonicated for 5 s twice using a Sonic Dismembrator
Model 100 at level 4. Cells were centrifuged for 10 min at
14,000  g to get clear supernatants. Supernatants were col-
lected and protein concentrations were quantified using the
Bradford method (Bio-Rad protein assay dye reagent) and
bovine serum albumin (BSA, EMD Millipore) as a standard.
Proteins in SDS gel-loading buffer (4% (v/v) SDS, 0.2% (v/v)
bromphenol blue, 20% (v/v) glycerol, 20 mM -mercaptoetha-
nol) were run on SDS-PAGE and transferred onto PVDF (poly-
vinylidene fluoride) membranes for Western blot analysis.
After blocking in 5% skim milk solution in PBS-T (1 PBS
containing 0.2% Tween 20), each membrane was incubated
with specific primary Abs overnight at 4 °C. After washing 3
times using PBS-T for 5 min, membranes were incubated in 5%
skim milk in PBS-T containing secondary Abs at 1:5000 dilu-
tions for 1 h at room temperature. After PBS-Twashing 3 times
each for 5 min, Western Lighting Enhanced Chemilumines-
cence solution (PerkinElmer Life Sciences) was added onto
membranes for 2 min, and x-ray films (Hyblot CL autoradio-
graph film, Denville Scientific, Inc.) were exposed to the mem-
branes. The resulting films were developed using a Kodak
X-Omat 2000A processor. To re-probe membranes with other
Abs, membranes were incubated in a striping buffer (2% SDS,
62.5 mM Tris (pH 6.8), 100 mM -mercaptoethanol) for 15 min
at 50 °C, washed 3 timeswith PBS-T, blocked in 5% skimmilk in
PBS-T, and developed as described above. Results on x-ray
films were scanned using a DuoScan T1200 scanner (Agfa).
Quantification of each band signal was performed using Quan-
tity One analysis software (Bio-Rad). Signals were normalized
to the levels of loading controls (-actin or non-phosphorylated
form of the proteins of interest).
Immunoprecipitations—Cells were harvested, lysed, and
incubated on ice for 10 min. Cell extracts were sonicated twice
for 5 s using a Sonic Dismembrator Model 100 at level 4. After
clearance by centrifugation at 16,500  g at 4 °C for 10 min,
supernatants were collected for protein quantification. 1 mg of
protein of each cell lysate was used for IP. Samples were pre-
cleared by incubation with protein A/G-Sepharose for 45 min,
and then supernatants were incubated with primary Abs
against the target protein for 3 h under gentle rotation at 4 °C.
Next, the samples were incubated with protein A/G-Sepharose
for an additional hour, continuing rotation at 4 °C. Immuno-
precipitates were washed in lysis buffer for 5 min four times,
resuspended in SDS gel-loading buffer, and analyzed by West-
ern blotting.
-Protein Phosphatase Treatment—Immunoprecipitated pro-
teins on beadswerewashed 4 timeswith lysis buffer and equally
divided into two aliquots. The samples were then washed with
1 -protein phosphatase (-PPase) buffer (50 mM Tris-HCl,
0.1 mMNa2EDTA, 5mMDTT, 0.01% (v/v) Brij 35 (pH 7.5)) two
times, and treated with or without 400 units of -PPase (New
England Biolabs) in 1 -PPase buffer at 30 °C for 30min in the
presence of 2 mM MnCl2. Reactions were stopped by adding
5 SDS gel-loading buffer.
Transfection of Cells with Plasmid Constructs and siRNAs—
HeLa and HEK-293 cells (catalog numbers CCL-2 and CRL-
1573; American Type Culture Collection (ATCC)) were main-
tained in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS) and 1% pen-
icillin/streptomycin (all fromGibco). For transient transfection
with single siRNA, cells were seeded on 60-mm cell culture
dishes shortly before transfection. siRNA transfection was per-
formed using HiPerFect transfection reagent (Qiagen) accord-
ing to themanufacturer’s protocol using 20 nM siRNAand 20l
of HiPerFect reagent for each dish. Transient transfection of
cells with plasmid DNAs alone or co-transfection of siRNA
with plasmids was performed using LipofectamineTM 2000
(Invitrogen). Cells were seeded on 60-mm cell culture dishes 1
day before transfection. Cells were transfected according to the
manufacturer’s recommended protocol using 3 g of plasmids
with 10l of Lipofectamine 2000 transfection reagent or 20 nM
siRNA oligos and 3 g of plasmids with 10 l of Lipofectamine
2000 transfection reagent for each dish.
Cell Cycle Synchronization—HeLa cells were synchronized at
S phase by double thymidine block. Cells were treated with 2
mM thymidine for 18 h, followed by 8 h of release in fresh
DMEM, and then, re-treated with thymidine for 18 h. For M
phase, cells were synchronized using nocodazole treatment.
For un-transfected cells, 3–5 h after seeding, cells were treated
with 100 ng/ml of nocodazole (Sigma) for 16–17 h, followed by
PBS washes twice and incubation in fresh DMEM for 30 min.
For synchronization of plasmid-transfected cells at M phase,
24–29 h after transfection, cells were changed into fresh
DMEMcontaining 100 ng/ml of nocodazole (Sigma), and incu-
bated for 16–17 h. Cells were then washed twice in PBS and
incubated in fresh DMEM for 30 min. The different cell cycle
stages were confirmed by flow cytometry analysis.
Flow Cytometry Analysis—After transfection, with or with-
out synchronization, cells were harvested with trypsin/EDTA
(0.25%, Invitrogen), washed twice with PBS, re-suspended in
500 l of PBS, and then fixed with 500 l of ethanol for at least
24 h. After centrifugation at 2,095 g for 10min, the cell pellets
were re-suspended in a mixture of 500 l of PBS and 500 l of
propidium iodide solution (Molecular Probes) containing ribo-
nuclease A (RNase A, Sigma) and Triton X-100 (Fisher Scien-
tific). The prepared samples were sent to the Flow Cytometry
Core Facility (University of Calgary) for cell cycle profiling
using a BD Biosciences FACScan flow cytometer.
Treatment with CDK Inhibitors—HeLa cells were seeded on
100-mm cell culture dishes at a density of 2 106 cells per dish.
3 h after seeding, cells were treated with 100 ng/ml of nocoda-
zole for 16 h. Mitotic cells were incubated with dimethyl sulf-
oxide (as a vehicle control), 20 or 40 mM drugs (roscovitine or
alsterpaullone) for 30 min in the presence of nocodazole in the
medium. After treatment, cells were trypsinized, and washed
twice in PBS. After centrifugation, cell pellets were dissolved in
lysis buffer containing protease inhibitor mixture tablets
(Roche) and 1 M microcystin-LR (Cayman Chemical). The
prepared cell lysates were used for IP experiments. CDK inhib-
itor experiments were performed in triplicate.
Antibodies—Primary Abs against Cdk1, Cdk2 (Santa Cruz),
Thr(P)72 TPX2 (homemade, described above), Cyclin B (Abcam),
TPX2 Phosphorylation at Thr72
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-actin (Chemicon), TPX2 (clone 183, epitope: 150–200 amino
acids of human TPX2, Novus Biologicals; clone 184, epitope:
700–749 amino acids of TPX2, Novus Biologicals), phospho-
Cdk/MAPK substrates (34B2, Cell Signaling), Cy3 conjugated-
-tubulin (Sigma), p-Aurora A (ab18318, Abcam), and mono-
clonal TPX2 (18D5-1, Abcam) were used for Western blots,
immunoprecipitations, and/or immunofluorescence experi-
ments. Donkey anti-rabbit IgGHRP and sheep anti-mouse IgG
HRP fromGEHealthcarewere used as secondaryAbs forWest-
ern blots. For immunofluorescent staining, Cy3- and FITC-
conjugated anti-mouse IgG or anti-rabbit IgG (Jackson Immu-
noResearch) were used.
Quantification of the Cells with Monopolar, Bipolar, and
Multipolar Mitotic Spindles—HeLa cells were seeded on glass
coverslips at a density of 5  104 cells/well in 24-well cell cul-
ture plates. The next day, cells were transfected with 1 g of
each plasmid (GFP, GFP-TPX2WT, or GFP-TPX2T72A). 24 h
after transfection, cells were synchronized with nocodazole
(100 ng/ml) for 16 h. Cells were then released from the nocoda-
zole block by washing three times in PBS and incubated in fresh
medium for 30 min. Cells were fixed with 4% PFA and stained
with Cy3-conjugated -tubulin antibody for mitotic spindle
visualization. Samples were observed under a fluorescence
microscope and GFP-positive (transfected) cells in prometa-
phase or metaphase were categorized into three different
classes based on the number of spindle poles: monopolar, bipo-
lar, and multipolar spindles. Over 100 prometaphase or meta-
phase cells were scored per slide and five separate slides were
examined for condition. The percentages of cells in each exper-
imental group were calculated. The differences in the mean
values for each group were analyzed by ANOVA. In a separate
experiment, HeLa cells were seeded on glass coverslips in
24-well cell culture plates (5 104 cells/well). The next day, 20
pmol of TPX2 UTR siRNA duplexes (to deplete endogenous
TPX2) were co-transfected with 500 ng of each plasmid (an
empty GFP vector, GFP-TPX2 WT, or GFP-TPX2 T72A) into
cells using 2l of Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. 24 h after transfection, cells were
synchronized with nocodazole (100 ng/ml) for 16 h. Cells were
then washed 3 times in PBS and released into fresh medium for
30 min. Fixation and quantification were performed exactly as
described above.
Immunofluorescent Staining, Signal Quantification, and
Confocal Microscopy Analysis—Cells on coverslips were fixed
with 4% PFA (4% paraformaldehyde in 1 PBS (pH 7.4)) for 10
min at 37 °C. Fixed cells were washed with PBS twice and
blocked in blocking buffer (3% BSA, 0.2% Triton-X 100 in 1
PBS) for 1 h at room temperature. Next, coverslips were incu-
bated with primary Abs in blocking buffer overnight at 4 °C.
After washes in PBS, coverslips were incubated with secondary
Abs conjugated with Cy3 or FITC (Jackson ImmunoResearch),
followed by DAPI staining for DNA visualization. After three
washes in 1 PBS, cells on coverslips were mounted on micro-
slides (VWR international) using a drop of Aqua-Mount
(Thermo Scientific). Images were acquired by a Nikon
D-Eclipse C1 confocal microscope with its EZ-C1 software. For
the quantitative analysis of exogenous EGFP-TPX2, Thr(P)288
Aurora A, and -Tubulin immunofluorescent signals, acquired
images were processed and analyzed using Adobe Photoshop
CS8.0 and ImageJ-win64. Integrated intensity was calculated at
the cellular level and/or at specific subcellular locations. Spin-
dle length was determined using ImageJ by calculating the dis-
tance between spindle poles inferred from the EGFP-TPX2
signals.
Blocking Peptide Experiments—The sequence of the blocking
peptide is LQQAIVTPLKPVD (from 66 to 78 amino acids of
human TPX2) and is exactly the same sequence used to gener-
ate the phosphospecific TPX2 Abs at Thr72. The threonine
amino acid has been phosphorylated. The generation and puri-
fication of the blocking peptidewas performed at theUniversity
of Calgary peptide service facility. The peptide was synthesized
on preparative HPLC (a Waters HPLC system) using a Vydac
C18 column. Phosphothreonine peptide modification was
carried out using standard N-(9-fluorenyl)methoxycarbonyl
chemistry (N--(9-fluorenyl)methoxycarbonyl-O-benzyl-L-
phosphothreonine derivative reagent was used to prepare this
phosphothreonine peptide). The quality of the peptide was
evaluated by analytical HPLC and mass spectrometry. Purity
assessment by analytical HPLC showed a single peak represent-
ing almost 100% purity of this peptide (the assessment was per-
formedby theUniversity ofCalgary peptide service facility). For
the blocking experiments, the Abs were combined with a 5-,
10-, 20-, and 50-fold excess of blocking peptide and preincu-
bated at 4 °C overnight.
Statistical Analysis—Data analysis to determine p values was
performed using an unpaired Student’s t test when comparing
two groups, or ANOVA for comparing multiple groups. p val-
ues of 0.05 were considered statistically significant in both
unpaired Student’s t test andANOVA.TheNewman-Keuls test
was performed when difference between multiple groups was
revealed by ANOVA (significant p values).
RESULTS
Cdk1 and Cdk2 Phosphorylate TPX2 in Vitro—Thr72 is a
highly conserved residue among human, mouse, rat, and frog
TPX2 (Fig. 1A). This residue is one of the uncharacterized
TPX2 phosphorylation sites that commonly appear in several
human phosphoproteome studies (19–32). It lies within a con-
sensus sequence recognized by Cdk1, Cdk2, and Cdk5, an atyp-
ical Cdk active in post-mitotic cells (34). Consistent with pre-
vious studies (19–32), we also detected phosphorylation of
Thr72 in synchronizedmitotic HeLa cells usingmass spectrom-
etry. Indeed, following immunoprecipitation with pan-TPX2
Abs from mitotic HeLa cell lysates, the existence of phospho-
Thr72 (Thr(P)72) TPX2 was confirmed by identification of
Thr(P)72 peptides by LC-MS/MS analysis (Fig. 1B). 14 addi-
tional putative phosphorylation sites identified in previous
studies (17, 19–32) were also found in our analysis (Fig. 1C).
We first generated polyclonal antibodies specific to Thr(P)72
TPX2 (Thr(P)72 TPX2 Abs, see “Experimental Procedures”).
We then performed in vitro phosphorylation assays of GST-
TPX2 fusion proteins with or without mutation at Thr72 (GST-
TPX2, GST-TPX2 T72A, and GST-TPX2 T72E) using active
Cdk1-cyclin B andCdk2-cyclin A. The purposes of these exper-
iments were to determine whether Thr72 can be phosphory-
lated by Cdk1/2 and to test the specificity of the phospho-Abs
TPX2 Phosphorylation at Thr72
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in vitro. Using our homemade Thr(P)72 TPX2 Abs, we found
that GST-TPX2 is phosphorylated at Thr72 in vitro by Cdk1-
cyclin B and Cdk2-cyclin A (Fig. 1D). In addition, our in vitro
kinase assays revealed that the Thr(P)72 TPX2 Abs only recog-
nized purified wild-type TPX2 protein phosphorylated by
Cdk1/2 in vitro but not the mutated GST-TPX2 T72A and
GST-TPX2 T72E that cannot be phosphorylated (Fig. 1D).
Taken together, our results indicate that TPX2 is phosphoryl-
ated in vitro at Thr72 by Cdk1 and Cdk2. Also, our homemade
Thr(P)72 TPX2 Abs are specific to TPX2 phosphorylated at
Thr72 in vitro.
In Vivo Specificity of the Thr(P)72 TPX2 Antibodies—TPX2 is
phosphorylated at Thr72 by the mitotic Cdk1-cyclin B complex
in vitro (Fig. 1D) and Thr(P)72 TPX2 peptides are detected in
human cell lysates (including HeLa cells) bymass spectrometry
(Fig. 1B and Refs. 19–32). Thus, TPX2 phosphorylation at
Thr72 may occur during mitosis. For these reasons, we
employed mitotic HeLa cells (a cell line that has been thor-
oughly used for the study of TPX2 (5, 8, 33, 35–37)) to deter-
mine the specificity of the Thr(P)72 TPX2 Abs in vivo. HeLa
cells were transiently transfected with control siRNA or two
specific TPX2 siRNAs (siRNA#1 and #2, seeRefs. 33 and 36 and
“Experimental Procedures” for details and specificity of the
siRNAs) for 24 h, synchronized at M phase for 16 h, and then
lysed for Western blots. The intensity of the TPX2 major band
was significantly decreased by 67 and 70%, respectively, in sam-
ples treated with TPX2 siRNA #1 and #2 when compared with
control siRNA-treated samples (Fig. 2, A and B). Stripping of
the blots and re-development with pan-TPX2 Abs confirmed
that Thr(P)72 TPX2 Abs recognize TPX2 from mitotic HeLa
cells (Fig. 2, A and B). To test whether Thr(P)72 TPX2 Abs
recognize the Thr72-phosphorylated form of TPX2 in HeLa
cells, we transfected the cells with GFP-TPX2 WT or T72A.
24 h after transfection, we synchronized the cells at M phase
with nocodazole for 16 h prior to immunoprecipitation exper-
iments (Fig. 2C). One would expect that Thr(P)72 TPX2 Abs
only recognize the immunoprecipitated phosphorylated form
of wild-type TPX2 but not the T72A. We found that both
endogenous TPX2 and exogenous GFP-TPX2 fusion proteins
were immunoprecipitated with pan-TPX2 Abs. Importantly,
Thr(P)72 TPX2 Abs only recognize immunoprecipitated exog-
enous TPX2 from GFP-TPX2 WT-transfected cells, but not
from GFP-TPX2 T72A-transfected cells (Fig. 2C). Similarly,
endogenous TPX2 was detected with Thr(P)72 TPX2 Abs (Fig.
2C). Treatment of samples with -protein phosphatase abol-
ished the Thr(P)72 TPX2 Abs signals (Fig. 2C). Taken together,
our results indicate that Thr(P)72 TPX2 Abs are specific to
TPX2 phosphorylated at Thr72 in vivo.
TPX2 Phosphorylation at Thr72 Peaks at Mitosis in HeLa
Cells—Because the expression of TPX2 is cell cycle-dependent,
we next asked whether Thr72 phosphorylation is regulated dur-
ing cell cycle. For this experiment, HeLa cells were synchro-
nized atM phase by nocodazole block and, for comparison, at S
phase by double thymidine block. Cell cycle profiling con-
firmed the enrichment at S andMphases (Fig. 3A). Endogenous
TPX2 was then immunoprecipitated with pan-TPX2 Abs from
lysates of non-synchronized cells and cell synchronized at S or
M phase prior to Western blots with Thr(P)72 TPX2 and pan-
FIGURE 1. The evolutionary conserved Thr72 in human TPX2 is phosphory-
lated by Cdk1 andCdk2 in vitro. A, comparative alignment of part of human
TPX2 sequence (amino acids 41 to 80) with corresponding sequences from
other species (mouse, rat, and frog) usingDNAMAN software (Lynnon Corpo-
ration). The sequence alignment shows that Thr72 in human TPX2 is con-
served in all other species. B, schematic diagramof the experimental protocol
for mass spectrometry analysis (LC-MS/MS) using mitotic HeLa cells. HeLa
cells were synchronized at M phase by nocodazole treatment (100 ng/ml) for
16 h and released for 30 min after nocodazole washout. Endogenous TPX2
was immunoprecipitated from 10 mg of total protein using pan-TPX2 Abs
(clone 184). IP sample was run on SDS-PAGE and after Coomassie Blue stain-
ing, the bandwith thematching size to TPX2 (confirmed byWestern blotting
with TPX2 Abs, not shown) was cut out and sent for LC-MS/MS analysis. The
gray asterisk on the spectra of the phosphopeptide containing Thr72 indicate
the identified matched fragment ions on mass spectrometry. C, phosphoryl-
ation sites identified by mass spectrometry analysis on endogenous TPX2
immunoprecipitated from nocodazole-synchronized mitotic HeLa cells in
regards to the known TPX2 domains. All these sites have been identified
previously (17, 19–32) but not confirmed and analyzed. Thr72 is the first vali-
dated and functionally characterized phosphorylation site in human TPX2
(this study). D, in vitro kinase assay using purified Cdk1/2 proteins and phos-
phospecific Thr72 TPX2 Abs. Purified GST fusion protein TPX2 WT, GST-TPX2-
T72A, or GST-TPX2-T72E was incubated with each active Cdk-cyclin complex
in thepresenceof 1mMcoldATP.All kinase reactionswere stoppedbyadding
2 SDS sample buffer and the samples were run on SDS-polyacrylamide gel
electrophoresis followed by Western blot detection using the indicated
antibodies.
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TPX2 Abs (Fig. 3B). As shown in Fig. 3C, the levels of Thr(P)72
TPX2 are much higher inM phase cells compared with S phase
or non-synchronized cells. When the ratio Thr(P)72 TPX2/
TPX2 levels in non-synchronized cells was set at 1, the relative
levels of Thr(P)72 TPX2 in M phase cells were 3–4-fold
higher than those found for non-synchronized cells and S phase
cells (Fig. 3C). In summary, using our homemade Thr(P)72 Abs,
we demonstrate that TPX2 is phosphorylated at Thr72 in vivo in
a cell cycle-dependent manner, and this phosphorylation peaks
at M phase.
TPX2 Is Phosphorylated in Vivo at Thr72 by Cdk1/2—Thr72
was identified as a potential Cdk2 substrate from a mass spec-
trometry screen using 293 cell lysates (24). Our results showed
that TPX2 is phosphorylated at Thr72 by Cdk1 and Cdk2 in
vitro (Fig. 1D). In light of these findings, we sought to determine
whether TPX2 is also phosphorylated at Thr72 by Cdk1 and
Cdk2 in vivo. To test this, we treated HeLa cells with roscovi-
tine, a purine analog and well known inhibitor of the kinase
activity of Cdk1-cyclin B, Cdk2-cyclin A, and Cdk5/p35/p39/
p25 (38–40). Roscovitine does not target Cdk5 in HeLa cells
because of the absence of Cdk5 co-activators p25, p35, and p39
(41–43). Because Thr72 phosphorylation is highest at M phase
of the cell cycle (Fig. 3), we performed roscovitine treatment on
mitotic cells. HeLa cells were first synchronized with nocoda-
zole at M phase and then treated with two different concentra-
tions of roscovitine (20 and 40M) for 30min in the presence of
nocodazole to avoid premature exit from mitosis (44). Upon
treatment with roscovitine, the levels of Thr72 phosphorylation
significantly decreased when compared with levels in mitotic
cells treated with dimethyl sulfoxide as a control (Fig. 4A). To
monitor the efficacy of the treatment, we probed the blots with
commercial Abs that recognize phosphorylated proteins con-
taining PX(S*/T*)P or (S*/T*)PX(R/K) motif (S*, a phosphoser-
ine; T*, a phosphothreonine), often found in Cdk/MAPK sub-
strates. The intensities of the bands detected by these Abs in
samples derived from mitotic cells treated with roscovitine
were significantly decreased when compared with samples
treated with dimethyl sulfoxide (Fig. 4B). Importantly, no
changes in the levels of cyclin B1 or TPX2 were found in the
roscovitine-treated cells, indicating that they had remained in
mitosis (Fig. 4B). Taken together, our results indicate that ros-
covitine treatments worked well and that Thr72 phosphoryla-
tion in HeLa cells can be attenuated by Cdk1/2 inhibition.
Intracellular Localization of TPX2 Phosphorylated at Thr72
in HeLa Cells—In interphase, TPX2 is predominantly localized
in the nucleus (2, 5). During mitosis, TPX2 decorates the
mitotic spindle apparatus (2, 5). Phosphorylation of TPX2 at
Thr72 can possibly dictate its subcellular localization. Using
immunofluorescence staining and confocal microscopy, we
next determined the subcellular distribution of Thr(P)72 TPX2
in interphase and mitotic cells. We first tested the specificity of
our Thr(P)72 TPX2 Abs for immunostaining using antigen pre-
absorption with the corresponding blocking peptide (residues
66 to 78, LQQAIVpT72PLKPVD). As shown in Fig. 5, following
FIGURE 2. Thr(P)72 TPX2 antibodies are specific in Western blot for TPX2
phosphorylated at Thr72 in vivo. A, specificity of Thr(P)72 TPX2 for TPX2
protein testedby siRNA.HeLacellswere transfectedwith control siRNAorone
of two TPX2 siRNAs for 24 h and synchronized at M phase with nocodazole
treatment (100 ng/ml). Cells were harvested and lysed with lysis buffer. Sam-
ples were run on SDS-PAGE, followed by Western blotting, first probed with
the Thr(P)72 TPX2 Abs, then stripped and re-probed with pan-TPX2 (clone
184) Abs. Levels of actin were used as loading controls. B, bar graph quanti-
tation for the relative expression levels of Thr(P)72 TPX2 and TPX2 in control
and TPX2 siRNA-transfected cells. Each sample was compared with sample
treated with control siRNA. Relative expression levels of Thr(P)72 for control
siRNA, 10; TPX2 siRNA#1 (UTR), 0.3180.085; TPX2 siRNA#2 (Cds), 0.289
0.115. Relative expression levels of TPX2, control siRNA, 1 0; TPX2 siRNA #1,
0.335 0.0074; TPX2 siRNA #2, 0.304 0.091 (mean S.E.). n 4 samples,
from 4 independent experiments. Unpaired Student’s t test indicated all the
results are significant. ***, p 0.001. C, specificity of Thr(P)72 TPX2 tested by
the use of T72Amutant and -PPase treatment. HeLa cells were left untrans-
fected, transfected with an empty GFP vector, GFP-TPX2 WT, or GFP-TPX2
T72A mutant plasmids. 24 h after transfection, cells were synchronized with
nocodazole for 16 h, harvested, and lysed. TPX2 immunoprecipitation was
performed in each sample with TPX2 Abs (clone 183). Where indicated, IP
beads were treated with -PPase before SDS-PAGE. The blot was first probed
with the Thr(P)72 TPX2 Abs. After stripping, the same blot was re-probedwith
pan-TPX2 Abs (clone 184).
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the incubation with the blocking peptide, the Thr(P)72 TPX2
immunofluorescent signal was significantly diminished in both
mitotic and interphase cells. In contrast, the pan-TPX2 signal
remained intact. In interphase cells, Thr(P)72 TPX2 is
expressed at low levels and is localized in the nucleus (Fig. 5C).
This is the same localization pattern reported with pan-TPX2
Abs (10, 33, 36). Conversely, during mitosis Thr(P)72 TPX2 is
predominantly localized in the cytosol (Fig. 5, A and B). In
FIGURE 3. In vivoTPX2phosphorylation at Thr72 is cell cycle-dependent andpeaks atMphase.A, cell cycle profiles analyzed by flow cytometry analysis to
confirmcell synchronizationat eachphase.B, after IPswithpan-TPX2Abs (clone184),Westernblotswereprobed firstwith theThr(P)72 TPX2Absand then, after
stripping, re-probed with pan-TPX2 Abs (clone 184). The levels of -actin were used as loading controls. The levels of cyclin B1 were used as positive controls
to show that synchronization atMphaseworkedwell, as indicatedby thehigh level of cyclin B1 inMphase comparedwith that of S phase or non-synchronized
cells. TheWestern blot figures are representative of 3 independent experiments. The input blot is from themitotic samples. C, bar graphs for quantification of
relative levels of Thr72 phosphorylation are shown.Non-syn, non-synchronized cells (1 0);M, M phase cells (4.16 0.36); S, S phase cells (1.31 0.4); mean of
the relative levels of Thr(P)72 TPX2/TPX2 expression S.D., n 3 independent experiments; ***, non-syn versusMphase, p 0.001; **, M versus S phase, p
0.01; NS, not significant: non-syn versus S phase, all by unpaired Student’s t test.
FIGURE 4. Phosphorylation of TPX2 at Thr72 is inhibited by the Cdk inhibitor roscovitine. A, the levels of Thr(P)72 were reduced by roscovitine treatment.
HeLa cells were first treatedwith 100 ng/ml of nocodazole for 16 h and then once synchronized, treatedwith dimethyl sulfoxide (as a control), or 20 and 40M
roscovitine for 30min. Cells were harvested, lysed, and TPX2was immunoprecipitatedwith pan-TPX2 Abs (clone 184). SDS-PAGEwas performed and followed
by Western blotting with Thr(P)72 and pan-TPX2 Abs (clone 184). B, cyclin B1 levels were also used to confirm that roscovitine-treated cells had remained in
mitosis. The levels of p-Cdk/MAPK substrates (PX(S*/T*)P or (S*/T*)PX(R/K)motif)were also used to confirm the effectiveness of the treatment. Actin levelswere
used as loading control.
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agreement with the Western blot results on synchronized cells
(Fig. 3), levels of Thr(P)72 TPX2 were much higher in mitotic
cells than in interphase cells (Fig. 5).
To confirm the localization pattern of Thr(P)72 TPX2
detected with our homemade Abs, we next expressed at low
levels GFP-TPX2WT and T72A in HEK-293 cells and assessed
their distribution during spindle assembly. As shown in Fig. 5D,
GFP-TPX2 T72A was preferentially localized to the spindle,
whereas the GFP-TPX2WTwas found both on the spindle and
cytosol. The absence of GFP-TPX2 T72A in the cytosol is not
due to aweaker expressionwhen comparedwith the expression
of GFP-TPX2 WT (see Fig. 6). A significant difference in the
ratio spindle MTs-associated signal/total signal was observed
between WT and T72A (Fig. 5D). Together with the use of
blocking peptides, the correlation between the localization of
endogenous Thr(P)72 TPX2 and exogenous TPX2 proteins
confirms the specificity of our Thr(P)72 TPX2 Ab for immuno-
staining. In brief, our results indicate that phosphorylation of
Thr72 regulates the localization of TPX2 duringmitosis. Inabil-
ity to phosphorylate TPX2 at Thr72 impairs its distribution to
the cytosol and accumulates the protein on the spindle.
Phosphorylation of TPX2 at Thr72 Impacts the Number of
Mitotic Spindle Poles —Because TPX2 plays a key role in spin-
dle assembly and Thr72 phosphorylation of TPX2 peaks at M
phase (Fig. 3), we next asked whether Thr72 phosphorylation
regulates themitotic functions of TPX2. To do so, we examined
the effects of GFP-TPX2WT and GFP-TPX2 T72A on spindle
morphology. We first assessed the number of spindle poles in
HeLa cells. Cells in prometaphase and metaphase with mitotic
spindles were categorized into three different classes based on
the number of spindle poles: monopolar, bipolar, and multipo-
lar spindles (more than 2 poles) (see Fig. 6A for representative
examples). A previous study has shown that GFP-TPX2 over-
expression can generate cells with monopolar spindle, cells
with bipolar spindles undergoing normal cell cycle without any
problem, as well as cells with multipolar spindles (5). Among
these cells overexpressing GFP-TPX2,60% showedmarkedly
altered morphologies (including apoptotic features), 35%
were in interphase and6%were arrested inmitosis (5). In our
synchronized cell cultures GFP-TPX2 WT overexpression
induced monopolar spindle in 30% of cells and multipolar
spindles in 3% of cells at the detriment of cells with bipolar
spindle when compared with GFP overexpression (Fig. 6C).
Interestingly, GFP-TPX2 T72A mutant significantly increased
the proportion ofmitotic cells withmultipolar spindles by 9 and
12% when compared with cells transfected with GFP-TPX2
WT or GFP, respectively (Fig. 6C). The expression levels of
GFP-TPX2 WT and GFP-TPX2 T72A were similar and thus,
the results cannot be attributed to the levels of expression but
rather to the phosphorylation status of Thr72 (Fig. 6B).
To ascertain the effects ofGFP-TPX2T72A in themultipolar
spindles phenotype, we directly assessed the impact of GFP-
TPX2 T72A in cells with depletion of endogenous TPX2. We
used specific TPX2 UTR-targeting siRNA to partially knock-
FIGURE 5. Localization of Thr(P)72 TPX2 inHeLa and293 cells.Mitotic (A and B) and interphase (C) HeLa cells were stainedwith Abs directed against Thr(P)72
TPX2, TPX2, and tubulin or with the Thr(P)72 Abs pre-absorbed with blocking peptide at different ratios. A, in mitotic cells, TPX2 phosphorylated at Thr72 is
localized in the cytosol and does not strictly associate with the mitotic spindle. B, HeLa cells stained with pan-TPX2 and Thr(P)72 TPX2 Abs preincubated with
Thr(P)72 blocking peptides. C, during interphase, Thr(P)72 TPX2 is localized in the nucleus. Note that the expression levels of Thr(P)72 are much lower in
interphase cells than in mitotic cells. Note that only the Thr(P)72 signal was blocked. D, representative photographs of mitotic 293 cells transfected with
GFP-TPX2 WT (WT) and GFP-TPX2 T72A (T72A). Scatter plots show the GFP signal at microtubules relative to total GFP signal. GFP-TPX2 T72A is significantly
enriched onmicrotubules when comparedwith GFP-TPX2WT (GFP-TPX2WT (0.26 0.01, n 29) versusGFP-TPX2 T72A (0.39 0.02, n 22), group (mean
S.E.); ***, p 0.0001 by t test). Scale bar, 10 m.
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down endogenous TPX2 without altering the expression of
GFP-TPX2 or GFP-TPX2 T72A (see “Experimental Proce-
dures” and Refs. 33 and 36) for detailed information on TPX2
siRNA). For this particular experiment, we expressed GFP-
TPX2 and GFP-TPX2 T72A at levels comparable with levels of
endogenous TPX2 (Fig. 6D). Note that the total amount of
ectopic and endogenous TPX2 in these samples was similar to
levels of endogenous TPX2 in unmanipulated cells. We also
ensured that the levels of GFP-TPX2 WT and T72A mutant
expression were similar so that differences in the results would
not be attributed to variations in protein expression. In agree-
ment with previous work (6), we found that partial knockdown
of TPX2 caused cells to havemoremultipolar spindles (Fig. 6E).
Importantly, consistent with the first set of experiments with
endogenous TPX2 (Fig. 6C), transfection of GFP-TPX2 T72A
in the partial absence of endogenous TPX2 further increased
the frequency of cells with multipolar spindles when compared
with GFP-TPX2 (Fig. 6E) (0.25 versus 0.30 for the ratio of cells
FIGURE 6. Effects of GFP-TPX2 T72A on the polarity of mitotic spindles in HeLa cells with or without endogenous TPX2. A, representative photographs
of mitotic HeLa cells at prometaphase and metaphase with monopolar, bipolar, and multipolar mitotic spindle poles. Scale bar, 10 m. B, Western blots
showing the levels of endogenous TPX2, GFP-TPX2WT, and GFP-TPX2 T72A in cells with intact levels of TPX2. C, bar graphs showing the number of cells with
different mono-, bi-, or multipolar mitotic spindles in each group. Cells with mitotic spindles were fixed and stained with Cy3-conjugated tubulin for MT
visualization. GFP-TPX2 T72A expression results in a significant increase in the percentage of cells with multipolar spindles in the presence of endogenous
TPX2. ANOVA comparing the three groups shows high significance with p 0.001. Neuman-Keuls test was used to compare each group: GFP (1.49 0.47)
versus T72A (12.72 2.10), p 0.001; TPX2WT (3.36 0.40) versus T72A (12.72 2.10), p 0.001; group (mean S.E.); ***, p 0.001;NS, not significant (GFP
versus TPX2). At least 100 cells for each set of experiments were used for quantification, 5 independent experiments were performed. Error bars indicate S.E.D,
Western blots showing the levels of endogenous TPX2, GFP-TPX2 WT, and GFP-TPX2 T72A in HeLa cells co-transfected with GFP-vector, GFP-TPX2 WT, or
GFP-TPX2T72A togetherwith TPX2 siRNA targeting the3UTRof TPX2mRNA. E, bar graphs showing thenumberof cellswithdifferentmono-, bi-, ormultipolar
mitotic spindles in each group. Cells with mitotic spindles were fixed and stained with Cy3-conjugated tubulin for MT visualization. Knockdown of TPX2 in
GFP-transfected cells results in a significant 5.4% increase in multipolar spindles versus control cells without TPX2 depletion. GFP-TPX2 T72A expression
produces an even greater 9.8 and 7.5% increase in the percentage of cells with multipolar spindles when compared with GFP/TPX2 siRNA and GFP-TPX2
WT/TPX siRNA, respectively. n 3, ANOVA test was used the compare the four groups (p 0.01). The Neuman-Keuls test was used to compare the following
groups: control (with control siRNA) (2.43 0.41) versus GFP (7.94 1.5), p 0.05; GFP (7.94 1.5) versus TPX2 WT (10.13 1.2), NS; WT (10.13 1.2) versus
T72A (17.67 3.2), p 0.05; GFP (7.94 1.5) versus T72A (17.67 3.2), p 0.05; group (mean S.E.); *, p 0.05; NS, not significant. n at least 500 cells for
each set of experiments; 3 independent experiments were performed. Error bars indicate S.E.
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with multipolar spindles/cells with bipolar spindle in experi-
ments with no TPX2 knockdown (Fig. 6C) versus experiments
with partial TPX2 knockdown (Fig. 6E)). Of note, in our exper-
imental settings, GFP-TPX2 expression was not able to rescue
the multipolar spindles phenotype caused by TPX2 depletion
due to differences in time-dependent expression of the siRNA
and cDNA constructs. In summary, abolition of Thr72 phospho-
rylation caused a significant increase in the percentage of HeLa
cellswithmultipolar spindlepoles.Thus,Thr72phosphorylation is
important for formation of a bipolar spindle.
Phosphorylation of TPX2 at Thr72 Regulates the Activity of
Aurora A and Affects Spindle Length, a Reflective Measure of Eg5
Activity—Tight regulationofAuroraAandEg5 activities byTPX2
is essential for normal bipolar spindle formation (reviewed in Ref.
10). Specifically, the Aurora A binding domain on TPX2 (amino
acids 1–43) allows it to interactwith the kinase, resulting in kinase
activation. ActivatedAuroraA is key forMTnucleation and orga-
nization during spindle morphogenesis. Inactive or overactivated
Aurora A induces spindle abnormalities including a multipolar
spindles phenotype (11, 12). In parallel, reduced motor activity of
Eg5 by TPX2 is critical for MT cross-linking, sliding along MTs,
and generation of outward forces for spindle pole separation at
mitotic entry. Indeed, inhibition of the TPX2/Eg5 association
mediated through theC-terminal of TPX2 (amino acids 711–747)
causes alterations in mitotic spindle polarity, extra MT foci, and
enhancedMTnucleation around chromosomes (14, 15), whereas
inhibition of Eg5withmonastrol reduces the number of cells with
multipolar spindles (45).
Based on the multipolar spindles phenotype of T72A-ex-
pressing cells and the facts that the same phenotype is recapit-
ulated in cells with reduced or enhanced Aurora A activity (11,
12), or with disrupted Eg5/TPX2 interaction (i.e. cells with
enhanced Eg5 activity) (14, 15), but attenuated in cells with Eg5
inhibited bymonastrol (45), we sought to determine the activity
ofAuroraA andEg5 inTPX2T72A-expressing cells. Activation
of Aurora Awas determined by levels of phosphothreonine 288
(Thr(P)288, i.e. activated) Aurora A using immunofluorescence
and confocal microscopy, whereas Eg5 activity was monitored
indirectly withMTs spindle length. Longer spindle MTs would
be reflective of enhanced motor activity of Eg5 (14, 15). Using
these parameters, we found that GFP-TPX2 T72A significantly
enhances the levels of Thr(P)288 AuroraAwhen comparedwith
WT at the spindle poles (Fig. 7A). Furthermore, expression of
the mutant also augments MTs spindle length, suggestive of
altered Eg5 activity (Fig. 7B), without affecting the amount
of total -tubulin detected on the spindle (Fig. 7C). Taken
together, these results suggest that inability to phosphorylate
TPX2 at Thr72 results in overactivation of Aurora A and Eg5
during spindle assembly.
DISCUSSION
In the present study, we found that TPX2 is phosphorylated
by Cdk1 and Cdk2 at Thr72 in vitro and in vivo (Figs. 1 and 4).
Using homemade Abs specific for Thr(P)72 and mass spectrome-
try (Figs. 1 and 2), we further discovered that Thr72 phosphoryla-
tion peaks at M phase (Fig. 3), a stage of the cell cycle where the
expression of TPX2 is the highest and Cdk1 is active. Abolish-
ment of Thr72 phosphorylation with the use of the T72A
mutant significantly increases the proportion of cells withmul-
tipolar spindles, particularly in the absence of endogenous
TPX2 (Fig. 6), and this phenotype is associated with a mislocal-
ization of T72A (Fig. 5). Expression of TPX2 T72A also up-reg-
ulates the kinase activity of Aurora A and enhances spindle
length, a correlative measure of Eg5 motor activity (Fig. 7).
Deregulation of either activity has been shown to disturb for-
mation of bipolar spindle. Thus, phosphorylation of TPX2 at
Thr72 occurs in mitotic cells, regulates TPX2 localization, and
likely impacts spindle assembly via Aurora A and Eg5.
In the current literature, only three phosphorylation sites on
Xenopus TPX2 have been functionally characterized. Echkerdt
et al. (47) identified serine 204 in Xenopus TPX2 as a Plx1
(Xenopus Polo-like kinase 1) target. Plx1 kinase activity is
required for mitotic progression in Xenopus. When TPX2 is
phosphorylated at Ser204 by Plx1, TPX2 activates Aurora A.
Sequence comparison shows that this site is not conserved
between species and no research has been done to identify
equivalent phosphorylation sites in other species, including
human. The two other sites that have been characterized in
Xenopus TPX2 are tyrosine 8 and tyrosine 10 (48). These sites
are conserved between Xenopus and human TPX2 and are in
the domain that closely binds toAuroraA (49) and activates the
kinase. Mutations of both Tyr8 and Tyr10 to alanine prevent
binding of TPX2 to Aurora A, abolish Aurora A activation, and
also prevent TPX2 phosphorylation by Aurora A (48). Thus,
our study constitutes the first in vivo functional characteriza-
tion of a TPX2 phosphorylation site in human cells with impli-
cation for cancers (see below).
HowDoes Phosphorylation of TPX2 at Thr72 Regulate Spindle
Formation?—The balance between structural support by TPX2
andmotor force by Eg5, as well as a proper activation of Aurora
A are essential for normal bipolar spindle formation.We found
that the inability to phosphorylate TPX2 at Thr72 enhancesMT
spindle length, a measure of the activity of Eg5. In a mutually
non-exclusive scenario, we also discovered that TPX2 T72A
induces hyperactivation of Aurora A. During spindle assembly,
activation of Aurora A by TPX2 depends on RanGTP that
mediates the release of TPX2 from the inhibitory Importin
complex in the vicinity of mitotic chromosomes (reviewed in
Ref. 10). As the RanGTP concentration decreases at increasing
distance to mitotic chromatin, the highest concentration of
Importin-free TPX2 (translated into highest Aurora A activity)
is found near the chromosomes (10). The results obtained with
our homemade antibodies showing that Thr(P)72 TPX2 local-
izes at the cell periphery (Fig. 5, A and C), and the finding that
T72A accumulates aberrantly on the mitotic spindle (Fig. 5D)
where Aurora A activity is up-regulated (Fig. 7A) are all con-
sistent with the current model of TPX2-mediated spindle
assembly (10). Furthermore, because TPX2 controls the stabil-
ity of Aurora A (46), an accumulation of TPX2 T72A on the
spindle may prolong the stability and activation of Aurora at
this location (Fig. 7A). Thus, deregulation of Aurora A and Eg5
activity are likely to contribute to multipolar spindles pheno-
type and spindle anomalies observed in GFP-TPX2 T72A-ex-
pressing cells.
That the localization of proteins involved in spindle assembly
and function is tightly regulated by phosphorylation (as is
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shown in this study for TPX2) is not unprecedented. For
instance, during interphase nucleolin is a major protein local-
ized in the nucleoli. During mitosis, it relocalizes at the chro-
mosome periphery (50) but once phosphorylated by CDC2, it
associates with the spindle poles from prometaphase to ana-
phase (50–52). Nucleolin-depleted cells showed a prolonged
cell cycle with misaligned chromosomes and defects in spindle
organization. The staining pattern of endogenous Thr(P)72
TPX2 is reminiscent of the pattern displayed by mitotic
unphosphorylated nucleolin. These results suggest that
Thr(P)72 TPX2 may regulate spindle assembly in concert with
nucleolin. How this potential regulation is linked to the Eg5-de-
pendent and/or RanGTP/Aurora-dependent modulation of
spindle assembly remains to be determined. Future studies are
required to refine the mechanism(s) by which Thr72 phos-
phorylation ensures bipolar spindle formation.
Overexpression and Phosphorylation of TPX2 in Cancers—
TPX2 has been proposed as a biomarker and effector for cancer
progression based on its elevated levels in numerousmalignan-
cies (lung, pancreas, ovary, bone, carcinomas, breast, cervix,
FIGURE 7. Overactivation of Aurora A and increased spindle length, a measure of Eg5 activity, in TPX2 T72A-expressing cells. A–C show 293
mitotic cells (prometaphase/metaphase) previously transfected with GFP-TPX2 WT (WT) or GFP-TPX2 T72A (T72A) expression vectors. A, representative
photographs ofWT- and T72A-transfected cells stained for Thr(P)288, a phosphoresidue indicative of the activity of Aurora kinase A.Dotted circles identify
the poles. Scatter plots show the P-Aurora signal at centrosomes relative to total GFP signal. GFP-TPX2 T72A induces higher Aurora A activity than
GFP-TPX2WT (GFP-TPX2WT (0.07 0.01, n 13) versus GFP-TPX2 T72A (0.14 0.03, n 18); *, p 0.05 by t test). B, representative photographs of the
spindle length detected in mitotic 293 cells transfected with GFP-TPX2 WT or T72A. Scatter plots show the spindle length in both groups. T72A-
expressing cells display longer spindles than WT-expressing cells (GFP-TPX2 WT (58.95 2.12, n 18) versus GFP-TPX2 T72A (66.67 2.20, n 21); **,
p 0.01 by t test). C, representative images of the -tubulin signal detected in GFP-TPX2 WT and T72A-trasnfected 293 cells. No significant difference
was detected between these two groups (GFP-TPX2 WT (1.93 0.41, n 15) versus GFP-TPX2 T72A (1.97 0.49, n 13); NS, non significant by t test).
In all the panels: the group is the mean S.E.. Scale bar, 10 m.
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etc.) (see Table 2 of Ref. 10 for a summary of the recent large
body of evidence pointing to increased expression of TPX2 in
cancer cells and tissues). In addition to these “cancer-type spe-
cific” analyses, TPX2 is overexpressed in 53 of 193 (27%)
microarray assays that compared gene expression profiles of
various cancers with their normal tissue counterpart (13). The
involvement of TPX2 in cancers has been mostly associated
with deregulation of its spindle assembly actions. Indeed,
among 10,000 genes overexpressed in cancers, enhanced
expression of TPX2 was found to correlate best with the mag-
nitude of chromosomal instability (53), a consequence of
altered spindle function and important feature of cancers (54–
56). Thus, overexpression of TPX2 in numerous malignancies,
combined with its crucial function as a regulator of spindle
formation and mitosis, implicate TPX2 as potential driving
and/or modulatory force for carcinogenesis. Interestingly,
TPX2 regulates the oncogenic Aurora A kinase. Like tpx2,
aurora Amaps to chromosome 20q and the two genes seem to
be co-overexpressed in colorectal cancers (13, 57, 58). In light of
TPX2 being an activator of Aurora A, the two proteins, if co-
overexpressed, may form an oncogenic unit that is more path-
ogenic, and perhaps more malignant, than increased levels of
either TPX2 or Aurora A alone (13). In the same perspective,
overactivation of Aurora A by aberrant phosphorylation of
TPX2 at Thr72, as proposed in ourwork (Fig. 7), may contribute
to unravel the cancers-associated roles of TPX2. In addition to
HeLa cells (this study), the CST curation database of Phospho-
Site obtained by mass spectrometry reveals that TPX2 is also
phosphorylated at Thr72 in human gastric and lung cancer cell
lines. Furthermore, a somatic mutation compiled on COSMIC
(Catalogue of Somatic Mutation in Cancer) at base pair 214
(A 3 G) changing amino acid Thr72 into an alanine (T72A
mutation) is found in a human endometrium carcinoma. Addi-
tional phosphorylation-deadmutations at Thr72 are likely to be
discovered in the future. Thus, the use of TPX2T72Amutant in
our experiments appears to be highly relevant for the study of
TPX2 under physiological and cancer conditions.
Discoveredmore than 17 years ago, TPX2 has emerged as an
essential factor for spindle assembly andmitosis in human cells.
As altered spindle assembly underlies chromosomal instability
and TPX2 misregulation has been associated with numerous
cancers, our study uncovers novel aspects of the spindle biology
of TPX2, thereby refining its role as a marker and therapeutic
target in cancers. Recently, we discovered the first nuclear roles
for TPX2 in the amplification of phosphorylated histone vari-
ant H2AX (-H2AX), and chromatin remodeling (33, 36).
-H2AX is a key molecule that mounts the DNA damage
response so essential for cells to repair their damaged DNA,
survive, or self-eliminate to prevent genomic instability. Inabil-
ity to mount and control a proper DNA damage response, as
observed in cells with deregulated TPX2 (33, 36), contributes to
genomic instability and may result in several types of cancers.
Therefore, TPX2 deregulation may not only participate into
chromosome instability but also in other forms of genomic
instability in cancer cells (59). Our discovery of TPX2 regula-
tion by phosphorylation at Thr72 opens a new perspective to
study both interphase and mitotic functions of TPX2 with
implications for cancer research. Future experiments looking at
other phosphorylation sites will shed new light onto the physi-
ological and pathological roles of TPX2 in cancers.
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